Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53
The DOI matches its Crossref record; 28 of the 29 references it cites were found in a registry or an index.
Abstract
The gene p53 encodes a transcriptional activator of genes involved in growth arrest, DNA repair and apoptosis. Loss of p53 function contributes to tumour development in vivo. The transcriptional activation function of p53 is inactivated by interaction with the mdm2 gene product. Amplification of mdm2 has been observed in 36% of human sarcomas, indicating that it may represent an alternative mechanism of preventing p53 function in tumour development. To study mdm2 function in vivo, we generated an mdm2 null allele by homologous recombination. Mdm2 null mice are not viable, and further analysis revealed embryonic lethality around implantation. To examine the importance of the interaction of MDM2 with p53 in vivo, we crossed mice heterozygous for mdm2 and p53 and obtained progeny homozygous for both p53 and mdm2 null alleles. Rescue of the mdm2-/- lethality in a p53 null background suggests that a critical in vivo function of MDM2 is the negative regulation of p53 activity.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Mdm2 can recruit HDAC1 to p53 to remove these acetylation marks and allow for p53 ubiquitination and degradation [49] in in vitro and mouse models [47,50].”
From Acetylation: a new target for protein degradation in cancer (2025) · cites this paper as [50]
In the citing paper
“Loss of Mdm2 leads to cell death by apoptosis and embryonic lethality at the blastocyst stage, and this phenotype is completely rescued by concomitant deletion of p53 (Chavez-Reyes, et al., 2003; Jones, et al., 1995; Montes de Oca Luna, et al., 1995).”
From The Mdm network and its regulation of p53 activities: a rheostat of cancer risk (2014) · cites this paper as Montes de Oca Luna, et al., 1995
In the citing paper
“Mouse genetic models strongly suggest that MDM2 and MDMX are the two major p53 antagonists in vivo107,108”
From MDM2, MDMX and p53 in oncogenesis and cancer therapy (2013) · cites this paper as [107]
In the citing paper
“Mouse genetic models strongly suggest that MDM2 and MDMX are the two major p53 antagonists in vivo107,108 and that they exert non-overlapping inhibitory activities towards p53 (Refs 24,109).”
From MDM2, MDMX and p53 in oncogenesis and cancer therapy (2013) · cites this paper as [107]
In the citing paper
“The crucial importance of MDM2 in regulating p53 was demonstrated using Mdm2-null mice, which display very early embryonic lethality (Jones et al., 1995; Montes de Oca Luna et al., 1995).”
From p53 at a glance (2010) · cites this paper as Montes de Oca Luna et al., 1995
Citations
Cites
WAF1, a potential mediator of p53 tumor suppression
El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321
The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases.
Wade Harper, J. (1993) · Cell · doi:10.1016/0092-8674(93)90499-g · Cited by 5,651
Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Butel, J. S., & Bradley, A. (1992) · Nature · doi:10.1038/356215a0 · Cited by 4,649
Tumor suppressor p53 is a direct transcriptional activator of the human bax gene
Toshiyuki, M., & Reed, J. C. (1995) · Cell · doi:10.1016/0092-8674(95)90412-3 · Cited by 4,063
Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis.
Greenblatt, M. S., Bennett, W. P., Hollstein, M., & Harris, C. C. (1994) · PubMed · Cited by 3,463
Momand, J., Zambetti, G. P., Olson, D. C., George, D., & Levine, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90644-r · Cited by 3,113
Kastan, M. B., Zhan, Q., El-Deiry, W. S., Carrier, F., Jacks, T., Walsh, W. V., Plunkett, B. S., Vogelstein, B., & Fornace, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90593-2 · Cited by 3,047
p53-dependent apoptosis modulates the cytotoxicity of anticancer agents
Lowe, S. W., Ruley, H. E., Jacks, T., & Housman, D. E. (1993) · Cell · doi:10.1016/0092-8674(93)90719-7 · Cited by 2,925
p53 is required for radiation-induced apoptosis in mouse thymocytes
Lowe, S. W., Schmitt, E. M., Smith, S. W., Osborne, B. A., & Jacks, T. (1993) · Nature · doi:10.1038/362847a0 · Cited by 2,864
Thymocyte apoptosis induced by p53-dependent and independent pathways
Clarke, A. R., Purdie, C. A., Harrison, D. J., Morris, R. G., Bird, C. C., Hooper, M. L., & Wyllie, A. H. (1993) · Nature · doi:10.1038/362849a0 · Cited by 2,271
Research works printed but not linked: 1
- Greenblatt, M. S., Bennett, W. P., Hollstein, M. & Harris C. C. Cancer Res. 54, 4855–4878 (1994).
Cited by
Items 501–600 of 1,001
Dp1is required for extra-embryonic development
Kohn, M. J., Bronson, R. T., Harlow, E., Dyson, N. J., & Yamasaki, L. (2003) · Development · doi:10.1242/dev.00355 · Cited by 84
“…the Dp1-deficient embryos were due to excessive apoptosis in utero, then inactivation of p53could reduce this apoptosis leading to improved viability, as has been shown previously for Mdm2-deficient and XRCC4-deficient embryos (Gao et al., 2000; Jones et al., 1995; Montes de Oca Luna et al., 1995).”
Backgroundp76MDM2 Inhibits the Ability of p90MDM2to Destabilize p53
Perry, M. E., Mendrysa, S. M., Saucedo, L. J., Tannous, P., & Holubar, M. K. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.8.5733 · Cited by 83
DNMT1 represses p53 to maintain progenitor cell survival during pancreatic organogenesis
Georgia, S. K., Kanji, M., & Bhushan, A. (2013) · Genes & Development · doi:10.1101/gad.207001.112 · Cited by 76
Boesten, L. S. M., Zadelaar, S. M., De Clercq, S., Francoz, S., van Nieuwkoop, A., Biessen, E. A. L., Hofmann, F., Feil, S., Feil, R., Jochemsen, A. G., et al. (2006) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401973 · Cited by 70
Inhibition of p53 DNA Binding Function by the MDM2 Protein Acidic Domain
Cross, B., Chen, L., Cheng, Q., Li, B., Yuan, Z.-M., & Chen, J. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.228981 · Cited by 70
Singh, R. K., Iyappan, S., & Scheffner, M. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m610879200 · Cited by 70
Cyclin A-CDK Phosphorylation Regulates MDM2 Protein Interactions
Zhang, T., & Prives, C. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m011326200 · Cited by 70
Seavey, S. E., Holubar, M., Saucedo, L. J., & Perry, M. E. (1999) · Journal of Virology · doi:10.1128/jvi.73.9.7590-7598.1999 · Cited by 70
“The ability of MDM2 to regulate p53 is required not only for multiplication of cultured cells but also for the development of murine embryos (32, 45).”
BackgroundGenetic Modifiers of the p53 Pathway
Basu, S., & Murphy, M. E. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026302 · Cited by 77
“As evidence of this fact, the genetic knockout of MDM2 leads to early embryonic lethality, but this lethality is rescued by concomitant knockout of p53 (Montes de Oca Luna et al. 1995).”
BackgroundRegulation of the p53 Family Proteins by the Ubiquitin Proteasomal Pathway
Bang, S., Kaur, S., & Kurokawa, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms21010261 · Cited by 69
“MDM2 TAp73α * TAp73β * ∆Np73α ** Embryonically lethal [44,45] Oncogene [46–55] TA Domain [200] SAM Domain [222] 1999 [170–172] *”
BackgroundInfluentialp53 pathway is involved in cell competition during mouse embryogenesis
Zhang, G., Xie, Y., Zhou, Y., Xiang, C., Chen, L., Zhang, C., Hou, X., Chen, J., Zong, H., & Liu, G. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1617414114 · Cited by 69
“Deletion of either Mdm2 or Mdm4 resulted in embryonic lethality in mice, which could be rescued by concomitant deletion of p53 (8, 9).”
BackgroundRole of Pirh2 in Mediating the Regulation of p53 and c-Myc
Hakem, A., Bohgaki, M., Lemmers, B., Tai, E., Salmena, L., Matysiak-Zablocki, E., Jung, Y.-S., Karaskova, J., Kaustov, L., Duan, S., et al. (2011) · PLoS Genetics · doi:10.1371/journal.pgen.1002360 · Cited by 69
Regulation of p53 and MDM2 Activity by MTBP
Brady, M., Vlatković, N., & Boyd, M. T. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.2.545-553.2005 · Cited by 69
“Homozygous deletion of MDM2 is lethal in mice, whereas mice that possess homozygous deletion of both MDM2 and p53 are viable and develop normally (22, 37).”
BackgroundSmall Molecule Antagonists of the MDM2 Oncoprotein as Anticancer Agents
Buolamwini, J., Addo, J., Kamath, S., Patil, S., Mason, M., & Ores, M. (2005) · Current Cancer Drug Targets · doi:10.2174/1568009053332672 · Cited by 69
Mdm2 promotes Cdc25C protein degradation and delays cell cycle progression through the G2/M phase
Giono, L. E., Resnick‐Silverman, L., Carvajal, L. A., Clair, S. S., & Manfredi, J. J. (2017) · Oncogene · doi:10.1038/onc.2017.254 · Cited by 73
Malmlöf, M., Roudier, E. A., Högberg, J., & Stenius, U. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.a116.604953 · Cited by 68
Regulation of the Mdm2-p53 signaling axis in the DNA damage response and tumorigenesis
Carr, M. I., & Jones, S. N. (2016) · Translational Cancer Research · doi:10.21037/tcr.2016.11.75 · Cited by 80
“Mdm2 mice display peri-implantation lethality due to unregulated p53 activity, and crossing these mice with the p53-null allele completely rescues Mdm2-null mice (98,99).”
BackgroundStabilization of the MDM2 Oncoprotein by Mutant p53
Peng, Y., Chen, L., Li, C., Lu, W., Agrawal, S., & Chen, J. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.c000781200 · Cited by 68
The p53 response: Emerging levels of co-factor complexity
Coutts, A. S., & La Thangue, N. B. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.03.150 · Cited by 72
Germ Cell Apoptosis and DNA Damage Responses
Bailly, A., & Gartner, A. (2012) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-4015-4_9 · Cited by 70
Dangerous habits of a security guard: the two faces of p53 as a drug target
Gudkov, A. V., & Komarova, E. A. (2007) · Human Molecular Genetics · doi:10.1093/hmg/ddm052 · Cited by 73
“Germline deletion of Mdm2 results in p53-dependent embryonic lethality (44,45) and conditional stimulation of p53 function in mice without functional Mdm2 leads to rapid loss of lymphoid tissues and subsequent death of the animal (46).”
BackgroundZebrafish Models of p53 Functions
Storer, N. Y., & Zon, L. I. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a001123 · Cited by 76
“These embryos are completely rescued by p53 deficiency (Langheinrich et al. 2002), akin to observations in p53/Mdm2 double knockout mice (Jones et al. 1995; Montes de Oca Luna et al. 1995).”
BackgroundTollini, L. A., Jin, A., Park, J., & Zhang, Y. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.06.006 · Cited by 66
“…results in high levels of p53 protein and transcriptional activity, and early embryonic lethality in Mdm2−/− mice; this phenotype is rescued by concomitant deletion of Trp53, further demonstrating the essential role of Mdm2 in p53 regulation (Jones et al., 1995; Montes de Oca Luna et al., 1995).”
MDM2 inhibition rescues neurogenic and cognitive deficits in a mouse model of fragile X syndrome
Li, Y., Stockton, M. E., Bhuiyan, I., Eisinger, B. E., Gao, Y., Miller, J. L., Bhattacharyya, A., & Zhao, X. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad9370 · Cited by 77
“The MDM2-P53 interaction is not only necessary for early embryonic development (50, 51) but is also crucial for stem cell maintenance in adults (20).”
BackgroundHIPK2 neutralizes MDM2 inhibition rescuing p53 transcriptional activity and apoptotic function
Stefano, V. D., Blandino, G., Sacchi, A., Soddu, S., & D’Orazi, G. (2004) · Oncogene · doi:10.1038/sj.onc.1207656 · Cited by 83
Activation of an MDM2-specific Caspase by p53 in the Absence of Apoptosis
Pochampally, R., Fodera, B., Chen, L., Lu, W., & Chen, J. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.21.15271 · Cited by 66
Giovinazzi, S., Morozov, V. M., Summers, M. K., Reinhold, W. C., & Ishov, A. M. (2013) · Cell Death & Differentiation · doi:10.1038/cdd.2012.169 · Cited by 65
Hároníková, L., Bonczek, O., Zatloukalová, P., Kokas, F. Z., Kucerikova, M., Coates, P. J., Fåhræus, R., & Vojtěšek, B. (2021) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-021-00293-6 · Cited by 76
“embryonic lethality due to massive apoptosis, which is rescued by concomitant Trp53 deletion [9, 10].”
BackgroundIt’s Getting Complicated—A Fresh Look at p53-MDM2-ARF Triangle in Tumorigenesis and Cancer Therapy
Kung, C.-P., & Weber, J. D. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.818744 · Cited by 76
Wild type p53 reactivation: From lab bench to clinic
Selivanova, G. (2014) · FEBS Letters · doi:10.1016/j.febslet.2014.03.049 · Cited by 65
Huang, K., Tang, Y., He, L., & Dai, Y. (2015) · Oncology Reports · doi:10.3892/or.2015.4458 · Cited by 65
Identification of XBP1-u as a novel regulator of the MDM2/p53 axis using an shRNA library
Huang, C., Wu, S., Ji, H., Yan, X., Xie, Y., Murai, S., Zhao, H., Miyagishi, M., & Kasim, V. (2017) · Science Advances · doi:10.1126/sciadv.1701383 · Cited by 73
“The latter is a fundamental regulatory pathway critical for tumorigenesis and other biological and pathological functions, such as embryogenesis, DNA repair, and senescence (38, 39).”
BackgroundDistinct roles of Mdm2 and Mdm4 in red cell production
Maetens, M., Doumont, G., Clercq, S. D., Francoz, S., Froment, P., Bellefroid, E., Klingmuller, U., Lozano, G., & Marine, J.-C. (2007) · Blood · doi:10.1182/blood-2006-03-013656 · Cited by 64
Self-citationDifferential p53-Independent Outcomes of p19 Arf Loss in Oncogenesis
Chen, Z., Carracedo, A., Lin, H.-K., Koutcher, J. A., Behrendt, N., Egia, A., Alimonti, A., Carver, B. S., Gerald, W., Teruya-Feldstein, J., et al. (2009) · Science Signaling · doi:10.1126/scisignal.2000053 · Cited by 64
Initial testing of the MDM2 inhibitor RG7112 by the pediatric preclinical testing program
Carol, H., Reynolds, C. P., Kang, M. H., Keir, S. T., Maris, J. M., Gorlick, R., Kolb, E. A., Billups, C. A., Geier, B., Kurmasheva, R. T., et al. (2013) · Pediatric Blood & Cancer · doi:10.1002/pbc.24235 · Cited by 65
The Many Faces of MDM2 Binding Partners
Riley, M. F., & Lozano, G. (2012) · Genes & Cancer · doi:10.1177/1947601912455322 · Cited by 72
Self-citationXiong, X., Zhao, Y., Tang, F., Wei, D., Thomas, D. G., Wang, X., Liu, Y., Zheng, P., & Sun, Y. (2014) · eLife · doi:10.7554/elife.02236 · Cited by 72
“…an involvement of p53 during embryogenesis, the causal role played by p53 was best demonstrated by the total knockout of Mdm2 (Jones et al., 1995; Montes de Oca Luna et al., 1995) or Mdm4 (Parant et al., 2001; Finch et al., 2002; Migliorini et al., 2002) and by the knock-in (KI) of mutant…”
Mouse models to study the interaction of risk factors for human liver cancer.
Sell, S. (2003) · PubMed · Cited by 70
p53 Downregulates Its Activating Vaccinia-Related Kinase 1, Forming a New Autoregulatory Loop
Valbuena, A., Vega, F. M. D. L., Blanco, S., & Lazo, P. A. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.00069-06 · Cited by 67
“lowing ubiquitination, by the proteasome (35).”
MethodMurine Double Minute-2 Prevents p53-Overactivation-Related Cell Death (Podoptosis) of Podocytes
Thomasova, D., Bruns, H. A., Kretschmer, V., Ebrahim, M., Romoli, S., Liapis, H., Kotb, A. M., Endlich, N., & Anders, H.-J. (2015) · Journal of the American Society of Nephrology · doi:10.1681/asn.2014040345 · Cited by 63
Crippling p53 activities via knock-in mutations in mouse models
Iwakuma, T., & Lozano, G. (2007) · Oncogene · doi:10.1038/sj.onc.1210278 · Cited by 83
“To evaluate the in vivo function of the p53DP allele, crosses to determine the ability to rescue the p53dependentMdm2-null andMdm4-null lethal phenotypes were performed (Montes de Oca Luna et al., 1995; Parant et al., 2001).”
BackgroundSelf-citationAkakura, S., Yoshida, M., Yoneda, Y., & Horinouchi, S. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m100200200 · Cited by 73
The p53/MDM2/MDMX-targeted therapies – a clinical synopsis
Jiang, L., & Zawacka-Pankau, J. (2020) · Cell Death & Disease · doi:10.1038/s41419-020-2445-9 · Cited by 62
MDMX inhibits the p300/CBP-mediated acetylation of p53
Sabbatini, P., & McCormick, F. (2002) · DNA and Cell Biology · doi:10.1089/104454902320219077 · Cited by 62
“In addition, both MDMX and MDM2 are essential independent regulators of p53 function during development (Montes de Oca Luna et al., 1995; Parant et al., 2001).”
Bowen, M. E., McClendon, J., Long, H. K., Sorayya, A., Nostrand, J. L. V., Wysocka, J., & Attardi, L. D. (2019) · Developmental Cell · doi:10.1016/j.devcel.2019.05.015 · Cited by 68
TIGAR regulates glycolysis in ischemic kidney proximal tubules
Kim, J., Devalaraja-Narashimha, K. B., & Padanilam, B. J. (2014) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00459.2014 · Cited by 66
Osorio, E. M. V., Hoogeman, M. S., Bondar, L., Levendag, P. C., & Heijmen, B. J. M. (2009) · Medical Physics · doi:10.1118/1.3134242 · Cited by 69
Dazard, J.-E., Piette, J., Basset‐Séguin, N., Blanchard, J., & Gandarillas, A. (2000) · Oncogene · doi:10.1038/sj.onc.1203695 · Cited by 71
“However, MDM2 null mouse embryos, which die at an early stage of development, are rescued when p53 alleles are additionally deleted (Montes-De Oca Luna et al., 1995; Jones et al., 1995).”
BackgroundControl of Human PIRH2 Protein Stability
Logan, I. R., Sapountzi, V., Gaughan, L., Neal, D. E., & Robson, C. N. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m312712200 · Cited by 67
Negative Regulation of p53 Functions by Daxx and the Involvement of MDM2
Zhao, L., Liu, J., Sidhu, G. S., Niu, Y., Liu, Y., Wang, R., & Liao, D. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m406743200 · Cited by 63
p53 in the CNS: Perspectives on Development, Stem Cells, and Cancer
Mendrysa, S. M., Ghassemifar, S., & Malek, R. A. (2011) · Genes & Cancer · doi:10.1177/1947601911409736 · Cited by 74
AP-1 Repressor Protein JDP-2: Inhibition of UV-Mediated Apoptosis through p53 Down-Regulation
Piu, F., Aronheim, A., Katz, S., & Karin, M. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.9.3012-3024.2001 · Cited by 61
p53 downregulates the Fanconi anaemia DNA repair pathway
Jaber, S., Toufektchan, E., Lejour, V., Bardot, B., & Toledo, F. (2016) · Nature Communications · doi:10.1038/ncomms11091 · Cited by 61
A Balancing Act: p53 Activity from Tumor Suppression to Pathology and Therapeutic Implications
Wang, M., & Attardi, L. D. (2021) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-042320-025840 · Cited by 66
The p53–Mdm2 network in progenitor cell expansion during mouse postnatal development
Liu, G., Terzian, T., Xiong, S., Van Pelt, C., Audiffred, A., Box, N., & Lozano, G. (2007) · The Journal of Pathology · doi:10.1002/path.2238 · Cited by 61
“Since p53 515C /515C mice express a p53 protein deficient in apoptosis, we first asked whether this allele could rescue the p53-dependent apoptotic phenotype of Mdm2-null mice [10,12].”
BackgroundSelf-citationMDM2 recruitment of lysine methyltransferases regulates p53 transcriptional output
Chen, L., Li, Z., Zwolińska, A., Smith, M. A., Cross, B. L., Koomen, J. M., Yuan, Z.-M., Jenuwein, T., Marine, J., Wright, K. L., et al. (2010) · The EMBO Journal · doi:10.1038/emboj.2010.140 · Cited by 73
“Knockout of either MDM2 or MDMX in mice results in embryonic lethality because of ectopic activation of p53 (Montes de Oca Luna et al, 1995; Parant et al, 2001).”
BackgroundChemotherapy induces NEDP1-mediated destabilization of MDM2
Watson, I. R., Li, B. K., Roche, O., Blanch, A., Ohh, M., & Irwin, M. S. (2009) · Oncogene · doi:10.1038/onc.2009.314 · Cited by 69
“MDM2 is also a critical regulator of p53 during development, shown by the embryonic lethality phenotype of MDM2-null mice that is rescued by concomitant loss of p53 (Jones et al., 1995; Montes de Oca Luna et al., 1995).”
BackgroundHDM2 phosphorylation by MAPKAP kinase 2
Weber, H. O., Ludwig, R. L., Morrison, D. K., Kotlyarov, A., Gaestel, M., & Vousden, K. H. (2005) · Oncogene · doi:10.1038/sj.onc.1208389 · Cited by 74
“Although p53 activity is regulated by several other mechanisms, including two further ubiquitin ligases Pirh2 and COP1 (Leng et al., 2003; Dornan et al., 2004), in vivo studies have clearly illustrated the importance of HDM2 (Mdm2 in mice) in inhibiting p53 to allow normal growth and development (Jones et al., 1995; M…”
BackgroundDeciphering the acetylation code of p53 in transcription regulation and tumor suppression
Xia, Z., Kon, N., Gu, A. P., Tavana, O., & Gu, W. (2022) · Oncogene · doi:10.1038/s41388-022-02331-9 · Cited by 60
“Moreover, it had been known that the Mdm2 deficient mouse was embryonically lethal, and that this could be rescued by the knockout of p53 [55].”
BackgroundMDM2 promotes SUMO-2/3 modification of p53 to modulate transcriptional activity
Stindt, M., Carter, S. A., Vigneron, A. M., Ryan, K. M., & Vousden, K. H. (2011) · Cell Cycle · doi:10.4161/cc.10.18.17436 · Cited by 67
“The importance of this control is demonstrated by the MDM2knockout mouse, which is embryonic lethal due to an overactive p53, leading to widespread apoptosis.(15,16) Activation of p53 in response to stress is accompanied by a rapid stabilization of the p53 protein, reflecting an inhibition of MDM2.”
BackgroundMaking sense of ubiquitin ligases that regulate p53
Jain, A. K., & Barton, M. C. (2010) · Cancer Biology & Therapy · doi:10.4161/cbt.10.7.13445 · Cited by 66
“Lack of Mdm2 causes embryonic lethality and, in the category of embryonic regulation of p53, Mdm2 is the principle player.(20,21) Its functional partner, MdmX (Mdm4), which lacks the enzymatic capacity to ubiquitinate p53, also induces embryonic lethality when deleted but at a later stage of development.”
BackgroundIlluminating p53 function in cancer with genetically engineered mouse models
Garcia, P. B., & Attardi, L. D. (2014) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2013.12.014 · Cited by 59
NF-κB inhibits T-cell activation-induced, p73-dependent cell death by induction of MDM2
Busuttil, V., Droin, N. M., McCormick, L. L., Bernassola, F., Candi, E., Melino, G., & Green, D. R. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1006163107 · Cited by 66
“Genetic ablation of MDM2 is embryonically lethal, but can be rescued by deletion of p53 (29, 30).”
BackgroundMdm2 Is Required for Survival and Growth of p53-Deficient Cancer Cells
Feeley, K. P., Adams, C. M., Mitra, R., & Eischen, C. M. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0809 · Cited by 63
“C57Bl/6 Mdm2fl/fl and p53−/− mice (2), provided by Dr.”
InfluentialMdm2 Deficiency Suppresses MYCN-Driven Neuroblastoma Tumorigenesis In Vivo
Chen, Z., Lin, Y., Barbieri, E., Burlingame, S., Hicks, J. M., Ludwig, A. D., & Shohet, J. M. (2009) · Neoplasia · doi:10.1593/neo.09466 · Cited by 62
p53 in cancer: A paradigm for modern management of cancer
Steele, R. J., & Lane, D. P. (2005) · The Surgeon · doi:10.1016/s1479-666x(05)80041-1 · Cited by 66
Matijasevic, Z., Steinman, H. A., Hoover, K., & Jones, S. N. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.01108-07 · Cited by 58
The intestinal epithelium compensates for p53-mediated cell death and guarantees organismal survival
Valentin-Vega, Y. A., Okano, H., & Lozano, G. (2008) · Cell Death & Differentiation · doi:10.1038/cdd.2008.109 · Cited by 58
“A loxP-flanked Mdm2 allele (Mdm2 FM ) generated in our laboratory phenocopies the original Mdm2-null allele upon Cre recombination.(12,26) To address the in vivo role of Mdm2 in regulating p53 activity in tissues with high turnover capacity, we generated mice lacking Mdm2 exclusively in the intestinal epithelium using…”
MethodSelf-citationStress-specific response of the p53-Mdm2 feedback loop
Hunziker, A., Jensen, M. H., & Krishna, S. (2010) · BMC Systems Biology · doi:10.1186/1752-0509-4-94 · Cited by 65
Wu, H., & Leng, R. P. (2011) · Cell Cycle · doi:10.4161/cc.10.12.15882 · Cited by 58
Nayak, M. S., Yang, J., & Hait, W. N. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4533 · Cited by 57
“Knockout of MDM2 in mice is embryonic lethal (5).”
BackgroundThe mutant p53 mouse as a pre-clinical model
Jackson, J. G., & Lozano, G. (2013) · Oncogene · doi:10.1038/onc.2012.610 · Cited by 57
Self-citationCarstens, M. J., Krempler, A., Triplett, A. A., van Lohuizen, M., & Wagner, K. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m400408200 · Cited by 63
Arriola, E. L., Lopez, A. R., & Chresta, C. M. (1999) · Oncogene · doi:10.1038/sj.onc.1202391 · Cited by 68
“During normal development the Mdm2/p53 interaction is critical and deletion of the mdm2 gene causes lethality in mice carrying a functional p53 gene (Jones et al., 1995; Montes-de-Oca-Luna et al., 1995).”
BackgroundTied Up in Loops: Positive and Negative Autoregulation of p53
Lu, X. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a000984 · Cited by 58
A new PICT ure of nucleolar stress
Suzuki, A., Kogo, R., Kawahara, K., Sasaki, M., Nishio, M., Maehama, T., Sasaki, T., Mimori, K., & Mori, M. (2012) · Cancer Science · doi:10.1111/j.1349-7006.2012.02219.x · Cited by 66
Regulation of the MDM2‐p53 pathway by the ubiquitin ligase HERC2
García‐Cano, J., Sánchez‐Tena, S., Sala-Gaston, J., Figueras, A., Viñals, F., Bartrons, R., Ventura, F., & Rosa, J. L. (2019) · Molecular Oncology · doi:10.1002/1878-0261.12592 · Cited by 60
“Thus, while TP53 knockout mice are viable despite being prone to developing tumors (Donehower et al., 1992; Jacks et al., 1994), MDM2 or HERC2 knockout mice are lethal during embryonic phase (Cubillos-Rojas et al., 2016; Jones et al., 1995; Montes de Oca Luna et al., 1995).”
BackgroundTargeting the Ubiquitin-Mediated Proteasome Degradation of p53 for Cancer Therapy
DeVine, T., & Dai, M. (2013) · Current Pharmaceutical Design · doi:10.2174/1381612811319180009 · Cited by 62
Natural Product MDM2 Inhibitors: Anticancer Activity and Mechanisms of Action
Qin, J., Nag, S. A., Voruganti, S., Wang, W., & Zhang, R. (2012) · Current Medicinal Chemistry · doi:10.2174/092986712803988910 · Cited by 58
“The crucial role of MDM2 in p53 regulation is strongly supported by the fact that targeted deletion of the mdm2 gene in mice is embryonic lethal, but mdm2 mice can be successfully rescued by a simultaneous deletion of the TP53 gene, which encodes p53 [50].”
BackgroundTargeting tumor cells expressing p53 with a water-soluble inhibitor of Hdm2
Kitagaki, J., Agama, K., Pommier, Y. G., Yang, Y., & Weissman, A. M. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0063 · Cited by 62
“The significance of Hdm2/Mdm2 as a major regulator of p53 is underscored by the embryonic lethality of mdm2 / mice, which is rescued by loss of p53 (14, 15).”
BackgroundThe Status of p53 Oligomeric and Aggregation States in Cancer
de Oliveira, G. A. P., Petronilho, E. C., Pedrote, M. M., Marques, M. A., Vieira, T. C. R. G., Cino, E. A., & Silva, J. L. (2020) · Biomolecules · doi:10.3390/biom10040548 · Cited by 56
“In resting cells, p53 transcriptional activity is tightly controlled by the E3 ubiquitin protein ligase, MDM2, leading to p53 degradation and rapid turnover [8].”
BackgroundMdm2: A Regulator of Cell Growth and Death
Alarcon-Vargas, D., Takahashi, S., & Ronai, Z. A. (2003) · Advances in cancer research · doi:10.1016/s0065-230x(03)01001-7 · Cited by 65
Conditional allele of mdm2 which encodes a p53 inhibitor
Grier, J. D., Yan, W., & Lozano, G. (2002) · genesis · doi:10.1002/gene.10066 · Cited by 57
Self-citationPhelps, M., Phillips, A., Darley, M., & Blaydes, J. P. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m412334200 · Cited by 57
Mdm2 Mutant Defective in Binding p300 Promotes Ubiquitination but Not Degradation of p53
Zhu, Q., Yao, J., Wani, G., Wani, M. A., & Wani, A. A. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m102634200 · Cited by 57
Bishop, A. J. R., Hollander, M. C., Kosaras, B., Sidman, R. L., Fornace, A. J., & Schiestl, R. H. (2003) · PubMed · Cited by 66
Haines, D. S. (1997) · Leukemia & Lymphoma · doi:10.3109/10428199709051772 · Cited by 57
p53 as an intervention target for cancer and aging
Hasty, P., & Christy, B. A. (2013) · Pathobiology of Aging & Age-related Diseases · doi:10.3402/pba.v3i0.22702 · Cited by 56
MDM2 Mediates Ubiquitination and Degradation of Activating Transcription Factor 3
Mo, P., Wang, H., Lu, H., Boyd, D. D., & Yan, C. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.132597 · Cited by 62
p53 ubiquitination by Mdm2: A never ending tail?
Coutts, A. S., Adams, C., & Thangue, N. B. L. (2009) · DNA repair · doi:10.1016/j.dnarep.2009.01.008 · Cited by 72
Impact of RUNX2 on drug-resistant human pancreatic cancer cells with p53 mutations
Ozaki, T., Yu, M., Yin, D., Sun, D., Zhu, Y., Bu, Y., & Sang, M. (2018) · BMC Cancer · doi:10.1186/s12885-018-4217-9 · Cited by 64
“MDM2 deficiency promoted p53-dependent cell death in a variety of cells [70].”
BackgroundTumor suppressor p53 cross-talks with TRIM family proteins
Liu, J., Zhang, C., Wang, X., Hu, W., & Feng, Z. (2020) · Genes & Diseases · doi:10.1016/j.gendis.2020.07.003 · Cited by 60
“MDM2 knockout in mice results in embryonic lethality due to uncontrolled activation of p53 and p53mediated apoptosis, which can be rescued by p53 knockout, demonstrating the vital role of MDM2 in negative regulation of p53.(41,42) In addition to mediating proteasomal degradation of p53, MDM2 promotes p53 nuclear expor…”
BackgroundMDM2 Mediates p300/CREB-binding Protein-associated Factor Ubiquitination and Degradation
Jin, Y., Zeng, S. X., Lee, H., & Lu, H. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m309916200 · Cited by 56
Splicing DNA-damage responses to tumour cell death
Crighton, D., & Ryan, K. M. (2004) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2004.09.001 · Cited by 63
Sato, Y., Shirata, N., Kudoh, A., Iwahori, S., Nakayama, S., Murata, T., Isomura, H., Nishiyama, Y., & Tsurumi, T. (2009) · Virology · doi:10.1016/j.virol.2009.03.017 · Cited by 61
Levav-Cohen, Y., Goldberg, Z., Zuckerman, V., Grossman, T., Haupt, S., & Haupt, Y. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.03.152 · Cited by 63
Mdm2 and MdmX as Regulators of Gene Expression
Biderman, L., Manley, J. L., & Prives, C. L. (2012) · Genes & Cancer · doi:10.1177/1947601912455331 · Cited by 62
Enigma negatively regulates p53 through MDM2 and promotes tumor cell survival in mice
Jung, C., Lim, J. H., Choi, Y., Kim, D., Kang, K. J., Noh, S., & Im, D. (2010) · Journal of Clinical Investigation · doi:10.1172/jci42674 · Cited by 60
Oncogenic transformation and experimental models of human cancer
Anna, C. S. (2007) · Frontiers in bioscience · doi:10.2741/2661 · Cited by 63
“Activation of ARF is induced by high levels of mitogenic stimuli or the activation of oncogenes and leads to inhibition of MDM2 and increased expression of p53.”
BackgroundChernov, M. V., Bean, L. J., Lerner, N., & Stark, G. R. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m103170200 · Cited by 64
Metadata
- Authors
- de Oca Luna, R. M., Wagner, D. S., & Lozano, G.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Venue
- Nature
- Published
- 1995-11
- Volume
- 378
- Issue
- 6553
- Pages
- 203-206
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1969044026
- Semantic Scholar
- e682601f6b2b8de8fa63cc39518a1461943483bc
- Cited by
- 1,420
- References
- 29
- Citations by year
- 2026: 10 · 2025: 24 · 2024: 31 · 2023: 30 · 2022: 31 · 2021: 32 · 2020: 49 · 2019: 29 · 2018: 32 · 2017: 49 · 2016: 63 · 2015: 44 · 2014: 67 · 2013: 37 · 2012: 63
- FWCI
- 15.76
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Heat shock proteins research
- Keywords
- p53, MDM2, embryonic lethality, p53-MDM2 interaction, tumor suppressor, sarcoma, homologous recombination, DNA repair
- MeSH terms
- Animals, Base Sequence, Cell Line, Crosses, Genetic, Female, Genes, Lethal, Heterozygote, Homozygote, Male, Mice, Inbred C57BL, Molecular Sequence Data, Nuclear Proteins, Proto-Oncogene Proteins, Tumor Suppressor Protein p53, Gene Deletion, DNA Primers, Mice, Proto-Oncogene Proteins c-mdm2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.